American journal of cardiovascular drugs : drugs, devices, and other interventions

Keyphrases

Publications

2023

Wout W A van den Broek, Nabil Mani, Jaouad Azzahhafi, Jurrien M Ten Berg
CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Ezekwesiri Michael Nwanosike, Wendy Sunter, Muhammad Ayub Ansari, Hamid A Merchant, Barbara R Conway, Syed Shahzad Hasan
A Real-World Exploration into Clinical Outcomes of Direct Oral Anticoagulant Dosing Regimens in Morbidly Obese Patients Using Data-Driven Approaches. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Gilles Montalescot, John H Alexander, Angel Cequier-Fillat, Scott D Solomon, Alban Redheuil, Martin Hudec, Johanne Silvain, Nadjia Kachenoura, Adam Janas, Marek Orban, Isabelle Josse, Fabrice Balavoine, Bruno Besse
Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Jie Feng, Yan-Qing Wu
Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Michael Böttcher, Hans-Dirk Düngen, Vasile Corcea, Frank Donath, Rainard Fuhr, Pim Gal, Gerd Mikus, Dietmar Trenk, Martin Coenen, Philippe Vieira Pires, Claudia Maschke, Antonios Othon Aliprantis, Nina Besche, Corina Becker
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Nan Zheng, Jinyan Zhong, Xi Chen, Jia Su, Chengjiang Liu, Longfu Jiang
Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Mason W Freeman, Mary Bond, Brian Murphy, James Hui, Jonathan Isaacsohn
Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Rahul Bhambri, A Carmine Colavecchia, Marianna Bruno, Yong Chen, Jose Alvir, Anuja Roy, Jason Kemner, Aaron Crowley, Darrin Benjumea, Lauren Gilstrap
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Hideyuki Takimura, Atsumasa Kurozumi, Rintaro Taniguchi, Ippei Tsuzuki, Emi Tajima, Yukihiro Yamaguchi, Mami Kawano, Yukako Takimura, Satoru Nishio, Masatsugu Nakano, Reiko Tsukahara
Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
James E Frampton
Inclisiran: A Review in Hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Mason W Freeman, Mary Bond, Brian Murphy, James Hui, Jonathan Isaacsohn
Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)
Aziz Rezapour, Mahsa Tashakori-Miyanroudi, Majid Haghjoo, Mohammad Barzegar, Parvin Tatarpour, Aghdas Souresrafil, Hassan Abolghasem Gorji, Negar Yousefzadeh, Mohammadreza Sheikhy-Chaman
Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review. American journal of cardiovascular drugs : drugs, devices, and other interventions (2023)

volume 23, number 1, 2023

Qiang Zhou, Zhiqiang Wang, Heming Wang, Zhidong Chen, Xiaoyi Li, Xiangrong Dai, Yong Zhang, Xiaohui Yu, Renpeng Zhou, Wei Hu
Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (1) (2023)
Qiang Zhou, Zhiqiang Wang, Heming Wang, Zhidong Chen, Xiaoyi Li, Xiangrong Dai, Yong Zhang, Xiaohui Yu, Renpeng Zhou, Wei Hu
Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (1) (2023)
Qiang Zhou, Zhiqiang Wang, Heming Wang, Zhidong Chen, Xiaoyi Li, Xiangrong Dai, Yong Zhang, Xiaohui Yu, Renpeng Zhou, Wei Hu
Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (1) (2023)
Qiang Zhou, Zhiqiang Wang, Heming Wang, Zhidong Chen, Xiaoyi Li, Xiangrong Dai, Yong Zhang, Xiaohui Yu, Renpeng Zhou, Wei Hu
Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers: Multiple Oral Dose-Escalation Phase I Trial. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (1) (2023)

volume 23, number 2, 2023

Hideyuki Takimura, Atsumasa Kurozumi, Rintaro Taniguchi, Ippei Tsuzuki, Emi Tajima, Yukihiro Yamaguchi, Mami Kawano, Yukako Takimura, Satoru Nishio, Masatsugu Nakano, Reiko Tsukahara
Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Gilles Montalescot, John H Alexander, Angel Cequier-Fillat, Scott D Solomon, Alban Redheuil, Martin Hudec, Johanne Silvain, Nadjia Kachenoura, Adam Janas, Marek Orban, Isabelle Josse, Fabrice Balavoine, Bruno Besse
Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
M Sakil Syeed, Teerawat Nonthasawadsri, Richard E Nelson, Nathorn Chaiyakunapruk, Surakit Nathisuwan
Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Michael Böttcher, Hans-Dirk Düngen, Vasile Corcea, Frank Donath, Rainard Fuhr, Pim Gal, Gerd Mikus, Dietmar Trenk, Martin Coenen, Philippe Vieira Pires, Claudia Maschke, Antonios Othon Aliprantis, Nina Besche, Corina Becker
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Aziz Rezapour, Mahsa Tashakori-Miyanroudi, Majid Haghjoo, Mohammad Barzegar, Parvin Tatarpour, Aghdas Souresrafil, Hassan Abolghasem Gorji, Negar Yousefzadeh, Mohammadreza Sheikhy-Chaman
Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
M Sakil Syeed, Teerawat Nonthasawadsri, Richard E Nelson, Nathorn Chaiyakunapruk, Surakit Nathisuwan
Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Rahul Bhambri, A Carmine Colavecchia, Marianna Bruno, Yong Chen, Jose Alvir, Anuja Roy, Jason Kemner, Aaron Crowley, Darrin Benjumea, Lauren Gilstrap
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
James E Frampton
Inclisiran: A Review in Hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Rahul Bhambri, A Carmine Colavecchia, Marianna Bruno, Yong Chen, Jose Alvir, Anuja Roy, Jason Kemner, Aaron Crowley, Darrin Benjumea, Lauren Gilstrap
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Hideyuki Takimura, Atsumasa Kurozumi, Rintaro Taniguchi, Ippei Tsuzuki, Emi Tajima, Yukihiro Yamaguchi, Mami Kawano, Yukako Takimura, Satoru Nishio, Masatsugu Nakano, Reiko Tsukahara
Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
M Sakil Syeed, Teerawat Nonthasawadsri, Richard E Nelson, Nathorn Chaiyakunapruk, Surakit Nathisuwan
Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Michael Böttcher, Hans-Dirk Düngen, Vasile Corcea, Frank Donath, Rainard Fuhr, Pim Gal, Gerd Mikus, Dietmar Trenk, Martin Coenen, Philippe Vieira Pires, Claudia Maschke, Antonios Othon Aliprantis, Nina Besche, Corina Becker
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Vivencio Barrios, Jose Moreno-Arribas, Santiago Heras, Nerea Fernandez-Ortiz, Diego Cazorla, María Amparo Quintanilla, Jose Maria Lopez-Ayala, Lorenzo Facila, Pilar Zuazola, Alberto Cordero
Increased Risk of Heart Failure in Elderly Patients Treated with Beta-Blockers After AV Node Ablation. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Rahul Bhambri, A Carmine Colavecchia, Marianna Bruno, Yong Chen, Jose Alvir, Anuja Roy, Jason Kemner, Aaron Crowley, Darrin Benjumea, Lauren Gilstrap
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Hideyuki Takimura, Atsumasa Kurozumi, Rintaro Taniguchi, Ippei Tsuzuki, Emi Tajima, Yukihiro Yamaguchi, Mami Kawano, Yukako Takimura, Satoru Nishio, Masatsugu Nakano, Reiko Tsukahara
Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Vivencio Barrios, Jose Moreno-Arribas, Santiago Heras, Nerea Fernandez-Ortiz, Diego Cazorla, María Amparo Quintanilla, Jose Maria Lopez-Ayala, Lorenzo Facila, Pilar Zuazola, Alberto Cordero
Increased Risk of Heart Failure in Elderly Patients Treated with Beta-Blockers After AV Node Ablation. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Wout W A van den Broek, Nabil Mani, Jaouad Azzahhafi, Jurrien M Ten Berg
CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Vivencio Barrios, Jose Moreno-Arribas, Santiago Heras, Nerea Fernandez-Ortiz, Diego Cazorla, María Amparo Quintanilla, Jose Maria Lopez-Ayala, Lorenzo Facila, Pilar Zuazola, Alberto Cordero
Increased Risk of Heart Failure in Elderly Patients Treated with Beta-Blockers After AV Node Ablation. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Michael Böttcher, Hans-Dirk Düngen, Vasile Corcea, Frank Donath, Rainard Fuhr, Pim Gal, Gerd Mikus, Dietmar Trenk, Martin Coenen, Philippe Vieira Pires, Claudia Maschke, Antonios Othon Aliprantis, Nina Besche, Corina Becker
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Vivencio Barrios, Jose Moreno-Arribas, Santiago Heras, Nerea Fernandez-Ortiz, Diego Cazorla, María Amparo Quintanilla, Jose Maria Lopez-Ayala, Lorenzo Facila, Pilar Zuazola, Alberto Cordero
Increased Risk of Heart Failure in Elderly Patients Treated with Beta-Blockers After AV Node Ablation. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Gilles Montalescot, John H Alexander, Angel Cequier-Fillat, Scott D Solomon, Alban Redheuil, Martin Hudec, Johanne Silvain, Nadjia Kachenoura, Adam Janas, Marek Orban, Isabelle Josse, Fabrice Balavoine, Bruno Besse
Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Wout W A van den Broek, Nabil Mani, Jaouad Azzahhafi, Jurrien M Ten Berg
CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Wout W A van den Broek, Nabil Mani, Jaouad Azzahhafi, Jurrien M Ten Berg
CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Rahul Bhambri, A Carmine Colavecchia, Marianna Bruno, Yong Chen, Jose Alvir, Anuja Roy, Jason Kemner, Aaron Crowley, Darrin Benjumea, Lauren Gilstrap
Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Michael Böttcher, Hans-Dirk Düngen, Vasile Corcea, Frank Donath, Rainard Fuhr, Pim Gal, Gerd Mikus, Dietmar Trenk, Martin Coenen, Philippe Vieira Pires, Claudia Maschke, Antonios Othon Aliprantis, Nina Besche, Corina Becker
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
James E Frampton
Inclisiran: A Review in Hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Gilles Montalescot, John H Alexander, Angel Cequier-Fillat, Scott D Solomon, Alban Redheuil, Martin Hudec, Johanne Silvain, Nadjia Kachenoura, Adam Janas, Marek Orban, Isabelle Josse, Fabrice Balavoine, Bruno Besse
Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Aziz Rezapour, Mahsa Tashakori-Miyanroudi, Majid Haghjoo, Mohammad Barzegar, Parvin Tatarpour, Aghdas Souresrafil, Hassan Abolghasem Gorji, Negar Yousefzadeh, Mohammadreza Sheikhy-Chaman
Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
James E Frampton
Inclisiran: A Review in Hypercholesterolemia. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Wout W A van den Broek, Nabil Mani, Jaouad Azzahhafi, Jurrien M Ten Berg
CYP2C9 Polymorphisms and the Risk of Cardiovascular Events in Patients Treated with Clopidogrel: Combined Data from the POPular Genetics and POPular AGE Trials. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)
Aziz Rezapour, Mahsa Tashakori-Miyanroudi, Majid Haghjoo, Mohammad Barzegar, Parvin Tatarpour, Aghdas Souresrafil, Hassan Abolghasem Gorji, Negar Yousefzadeh, Mohammadreza Sheikhy-Chaman
Cost Effectiveness of Adding Dapagliflozin to Standard Care in Heart Failure Patients with Reduced Ejection Fraction: A Systematic Review. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (2) (2023)

volume 23, number 3, 2023

Albert A Volkl, Kenneth Todd Moore, Lloyd Haskell, Elliot S Barnathan
Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (3) (2023)
Albert A Volkl, Kenneth Todd Moore, Lloyd Haskell, Elliot S Barnathan
Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (3) (2023)
Albert A Volkl, Kenneth Todd Moore, Lloyd Haskell, Elliot S Barnathan
Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease. American journal of cardiovascular drugs : drugs, devices, and other interventions 23 (3) (2023)